Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Ann Wilson

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Molecular testing in melanomaMelissa Ann Wilson, Katherine L Nathanson
Oncology|July 27, 2017
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the LiteratureKierstin Utter, Chloe Goldman, Sarah A Weiss, et al.
Oncology|June 12, 2017
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of CareChloe Goldman, Jeremy Tchack, Eric M Robinson, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cancer Journal (Sudbury, Mass.)|March 29, 2012
Molecular testing in melanomaMelissa Ann Wilson, Katherine L Nathanson
Oncology|July 27, 2017
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the LiteratureKierstin Utter, Chloe Goldman, Sarah A Weiss, et al.
Oncology|June 12, 2017
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of CareChloe Goldman, Jeremy Tchack, Eric M Robinson, et al.
Pageof 1